利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

13 条记录 (耗时 0.02 秒)

    BREAST CANCER PROTEINS
    1.
    发明申请
    BREAST CANCER PROTEINS 审中-公开
    乳腺癌蛋白

    公开(公告)号：US20110098234A1

    公开(公告)日：2011-04-28

    申请号：US11575228

    申请日：2005-09-14

    申请人： Michael Cahill ,  André Schrattenholz ,  Raffael Kurek

    发明人： Michael Cahill ,  André Schrattenholz ,  Raffael Kurek

    IPC分类号： A61K38/17 ,  A61P35/00 ,  C12Q1/02

    CPC分类号： G01N33/57415

    摘要： The present invention relates to a pooling method for performing proteomics with human samples, preferably derived from microdissected human samples, wherein the samples are grouped into two or more pools and each pool reveals at least one protein that is differentially manifest between these pools but common to a member of a given pool. Besides, the invention refers to proteins whose abundances are upregulated in cancer cells, especially in breast cancer cells, preferably in breast cancer cells that are positive or negative towards hormone binding receptors.

    摘要翻译： 本发明涉及一种用人类样品进行蛋白质组学的汇集方法，优选衍生自显微解剖的人类样品，其中将样品分组为两个或更多个池，每个泳池显示出在这些池之间差异显现的至少一种蛋白质， 一个给定池的成员。 此外，本发明涉及在癌细胞，特别是在乳腺癌细胞中，优选在对激素结合受体呈阳性或阴性的乳腺癌细胞中，其丰度上调的蛋白质。

    Muscarinic antagonists with parp and sir modulating activity as cytoprotective agents
    6.
    发明授权
    Muscarinic antagonists with parp and sir modulating activity as cytoprotective agents 失效
    毒蕈碱拮抗剂具有parp和sir调节活性作为细胞保护剂

    公开(公告)号：US08466144B2

    公开(公告)日：2013-06-18

    申请号：US11632649

    申请日：2005-07-18

    申请人： André Schrattenholz

    发明人： André Schrattenholz

    IPC分类号： A61K31/551 ,  A61P25/00

    CPC分类号： A61K31/554 ,  A61K31/55 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/5517 ,  A61K31/553

    摘要： The present invention relates to generally to the cytoprotective activity of mixed muscarinic inhibition/PARP modulation and in particular to the use of dual inhibitors of M1 muscarinic receptor and poly(ADP-ribose) polymerase (PARP) as neuroprotective medicaments, particularly as medicaments for the prevention and/or treatment of neurological diseases. Particularly preferred compounds are condensed diazepinones, e.g. condensed benzodiazepinones such as pirenzepine or compounds which are metabolized to condensed benzodiazepinones such as olanzapine.

    摘要翻译： 本发明一般涉及混合的毒蕈碱抑制/ PARP调节的细胞保护活性，特别涉及使用M1毒蕈碱受体和聚（ADP-核糖）聚合酶（PARP）的双重抑制剂作为神经保护药物，特别是作为药物 预防和/或治疗神经系统疾病。 特别优选的化合物是缩合的二氮杂酮，例如 缩合苯并二氮杂酮如哌仑西平或代谢为缩合苯并二氮杂酮如奥氮平的化合物。

    Muscarinic antagonists with PARP and SIR modulating activity as agents for inflammatory diseases
    8.
    发明授权
    Muscarinic antagonists with PARP and SIR modulating activity as agents for inflammatory diseases 失效
    具有PARP和SIR调节活性的毒蕈碱拮抗剂作为炎性疾病的药剂

    公开(公告)号：US08039464B2

    公开(公告)日：2011-10-18

    申请号：US11632648

    申请日：2005-07-18

    申请人： André Schrattenholz

    发明人： André Schrattenholz

    IPC分类号： A61P1/04 ,  A61P11/00 ,  A61P9/02 ,  A61P27/02 ,  A61P35/00

    CPC分类号： A61K31/554 ,  A61K31/55 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/5517 ,  A61K31/553

    摘要： The present invention relates generally to the cytoprotective activity of mixed muscarinic inhibition/PARP modulation and in particular to the use of dual inhibitors of M1 muscarinic receptor and poly(ADP-ribose) polymerase (PARP) as epithelioprotective medicaments, particularly as medicaments for the prevention and/or treatment of at least one of the common lung diseases associated with a significant inflammatory component such as severe sepsis, acute lung injury, acute respiratory distress syndrome, cystic fibrosis, asthma, allergic rhinitis, chronic obstructive pulmonary disease, pulmonary fibrosis, systemic sclerosis, pneumoconiosis or lung cancer. Particularly preferred compounds are condensed diazepinones, e.g. condensed benzodiazepinones such as pirenzepine or compounds which are metabolized to condensed benzodiazepinones such as olanzapine.

    摘要翻译： 本发明一般涉及混合毒蕈碱抑制/ PARP调节的细胞保护活性，特别涉及使用M1毒蕈碱受体和聚（ADP-核糖）聚合酶（PARP）的双重抑制剂作为上皮保护药物，特别是作为预防药物的药物 和/或治疗与显着的炎症成分相关的常见肺部疾病中的至少一种，例如严重脓毒症，急性肺损伤，急性呼吸窘迫综合征，囊性纤维化，哮喘，过敏性鼻炎，慢性阻塞性肺病，肺纤维化，全身性 硬化症，肺尘埃沉着病或肺癌。 特别优选的化合物是缩合的二氮杂酮，例如 缩合苯并二氮杂酮如哌仑西平或代谢为缩合苯并二氮杂酮如奥氮平的化合物。

    Use of finasteride, dutasteride and related compounds for the prevention or treatment of neurologically-associated disorders
    9.
    发明授权
    Use of finasteride, dutasteride and related compounds for the prevention or treatment of neurologically-associated disorders 失效
    使用非那雄胺，度他雄胺和相关化合物预防或治疗神经系统相关疾病

    公开(公告)号：US07998970B2

    公开(公告)日：2011-08-16

    申请号：US11720650

    申请日：2005-12-02

    申请人： Vukic Soskic ,  André Schrattenholz

    发明人： Vukic Soskic ,  André Schrattenholz

    IPC分类号： A61K31/473 ,  C07D221/18 ,  C07K14/47 ,  C12N9/02

    CPC分类号： C07J73/005 ,  A61K31/568 ,  A61K31/58 ,  A61K45/06 ,  A61K2300/00

    摘要： The present invention relates to new pharmaceutical uses of 4-azasteroid compounds, in particular of Finasteride/Dutasteride/Dutasteride and Dutasteride, particularly preferred of Finasteride/Dutasteride/Dutasteride, and its pharmaceutically acceptable derivatives, and combinations comprising said compounds. The invention also features generally the use of a modulator compound of neuroprotective conditions via beta subunits of shaker-type voltage-gated potassium channels and/or via members of solute carriers family 25, in particular Aralar (member 12) and adenine-nucleotide translocators 1 & 2 (member 4 & 5) and/or via a 4-nitrophenylphosphatase domain and non-neuronal SNAP25-like protein homolog 1 (NIPSNAP 1) as a neuroprotective medicament, particularly as a medicament for the prevention and/or treatment of neurological diseases such as dementia, Parkinson, Alzheimer, schizophrenia or epilepsy. The demonstrated inhibition of the MPTP appears to constitute a novel principle applicable to all pathological conditions which have underlying excitotoxic/mitochondrial mechanisms, like: amyotrophic lateral sclerosis, Alzheimer's disease, depression, epilepsy, multiple sclerosis, pain, Parkinson's disease, schizophrenia, traumatic brain and spinal chord injury, stroke and other ischemic conditions in the brain.

    摘要翻译： 本发明涉及4-氮杂甾族化合物，特别是非那雄胺/度他雄胺/度他雄胺和度他雄胺，特别优选非那雄胺/度他雄胺/度他雄胺及其药学上可接受的衍生物以及包含所述化合物的组合的新药用途。 本发明还通常特征在于通过振动筛型电压门控钾通道的β亚基和/或通过溶质载体家族25，特别是Aralar（成员12）和腺嘌呤核苷酸转运体1的成员通过神经保护条件的调节剂化合物的使用 ＆2（成员4＆5）和/或通过4-硝基苯基磷酸酶结构域和非神经元SNAP25样蛋白同系物1（NIPSNAP 1）作为神经保护药物，特别是作为预防和/或治疗神经疾病的药物 如痴呆症，帕金森病，阿尔茨海默病，精神分裂症或癫痫。 所显示的MPTP的抑制似乎构成适用于具有潜在兴奋性毒素/线粒体机制的所有病理状况的新颖原理，例如：肌萎缩性侧索硬化，阿尔茨海默病，抑郁症，癫痫，多发性硬化，疼痛，帕金森病，精神分裂症，创伤性脑 和脊髓损伤，脑卒中等缺血状况。